Orexo AB, (ORXOY.OB) a Swedish pharmaceutical company Friday announced positive data from a clinical study of OX640, a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions.
The company said OX640 treatments achieved clinically relevant plasma levels of epinephrine compared to the intramuscular reference product. Moreover, the pharmacokinetic and pharmacodynamic evaluation in subjects with and without allergic rhinitis supported rapid onset of effect in patients with airway symptoms.
OX640 formulations typically produced more pronounced increases in blood pressure and heart rate than the intramuscular injection, which are key effects for the treatment of anaphylaxis. There were no severe or serious adverse events.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.